Torsdag 14 Augusti | 21:07:01 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 N/A Bokslutskommuniké 2025
2025-08-21 07:30 Kvartalsrapport 2025-Q2
2025-06-30 - X-dag bonusutdelning GUBRA 61.2
2025-06-27 - Extra Bolagsstämma 2025
2025-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2025-04-03 - Årsstämma
2025-02-28 - Bokslutskommuniké 2024
2024-08-23 - Kvartalsrapport 2024-Q2
2024-04-04 - X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-01 - Extra Bolagsstämma 2023
2023-08-25 - Kvartalsrapport 2023-Q2

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
2025-08-12 10:42:00

Following a planned succession process, the Board of Directors of Gubra has appointed Markus Rohrwild as the new CEO of the company effective September 8, 2025. Henrik Blou will step down after almost 10 years as CEO.
 
Gubra Chair of the Board Monika Lessl said: “Henrik has done an outstanding job as CEO over the past almost 10 years, not least demonstrated by Gubra’s significant revenue growth. He played a key role in the successful IPO of Gubra in 2023 and has overseen a tremendous development since then, including the landmark out-licensing deal with AbbVie for the anti-obesity asset GUBamy earlier this year. We wish him all the best for the future. I am pleased to announce Markus Rohrwild as new CEO. Markus brings extensive international leadership experience from biotech and global healthcare, and I am confident that he is the right person to lead Gubra through its next phase of growth together with the rest of the leadership team and all of Gubra’s dedicated employees.”
 
Markus Rohrwild, a Swiss/German citizen, is an experienced biotech CEO, board member and global healthcare executive. He currently serves as the chair of the boards of Genevant Sciences GmbH and Roivant Sciences GmbH in Switzerland. Previously, he held several CEO/Managing Director positions within the Roivant Group, leading preclinical biotech ventures in immuno-oncology, infectious diseases, and telemedicine. Prior to that, Markus served as Global Head of the Cardio-Metabolic and Ophthalmology Business Franchises at Novartis Pharma. He holds a Ph.D. in Biological and Biomedical Sciences from Harvard University.
 
Henrik Blou, CEO of Gubra, said: “Almost 10 years ago I joined Gubra. A huge effort has been made by us as a team and propelled the company into a completely different league, and I am really excited and proud of what we have achieved. I have always admired leaders who found an appropriate point in time to step back, and I feel that now is the right moment to hand over the baton. We are in a very strong position and still have a lot of potential to unfold.
 
Incoming CEO of Gubra, Markus Rohrwild said: “I am very excited to join Gubra as CEO. The company's achievements and commitment to science and technology as well as the pipeline are remarkable. I look forward to driving continued value growth together with Gubra's highly skilled and passionate employees.”